Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
46
NMTC Quote, Financials, Valuation and Earnings
Last price:
$0.83
Seasonality move
:
66.87%
Day range:
$0.73 - $0.77
52-week range:
$0.55 - $1.72
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.97x
P/B ratio:
28.88x
Volume:
64.8K
Avg. volume:
229.8K
1-year change:
-43.4%
Market cap:
$23.7M
Revenue:
$3.5M
EPS (TTM):
-$0.46
Analysts' Opinion
-
Consensus RatingNeuroOne Medical Technologies has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, NeuroOne Medical Technologies has an estimated upside of 159.81% from its current price of $0.77.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.77.
Fair Value
-
According to the consensus of 0 analysts, NeuroOne Medical Technologies has 159.81% upside to fair value with a price target of -- per share.
NMTC vs. S&P 500
-
Over the past 5 trading days, NeuroOne Medical Technologies has underperformed the S&P 500 by -5.44% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NeuroOne Medical Technologies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NeuroOne Medical Technologies revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter NeuroOne Medical Technologies reported revenues of $272.3K.
Earnings Growth
-
NeuroOne Medical Technologies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter NeuroOne Medical Technologies reported earnings per share of -$0.11.
Enterprise value:
22.3M
EV / Invested capital:
27.11x
Price / LTM sales:
5.97x
EV / EBIT:
--
EV / Revenue:
6.45x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.00x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.1M
Return On Assets:
-208.1%
Net Income Margin (TTM):
-356.74%
Return On Equity:
-335.54%
Return On Invested Capital:
-335.54%
Operating Margin:
-1034.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $171.2K | $2M | $3.5M | $741.8K | $272.3K | |
| Gross Profit | -$70.8K | $456.5K | $1.1M | $193.7K | $141.1K | |
| Operating Income | -$10M | -$12M | -$11.9M | -$3.2M | -$2.8M | |
| EBITDA | -$9.9M | -$11.7M | -$11.8M | -$3M | -$3M | |
| Diluted EPS | -$0.63 | -$0.65 | -$0.46 | -$0.13 | -$0.11 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.2M | $7.3M | $12.2M | $7.3M | $4.6M | |
| Total Assets | $4.8M | $7.9M | $12.8M | $8.1M | $5.4M | |
| Current Liabilities | $2.4M | $1.2M | $3.1M | $1.8M | $2.2M | |
| Total Liabilities | $2.7M | $1.4M | $3.2M | $1.8M | $4.5M | |
| Total Equity | $2.1M | $6.6M | $9.6M | $6.2M | $822K | |
| Total Debt | $1M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.5M | -$12.9M | -$11M | -$2.9M | -$2.7M | |
| Cash From Investing | -$3.2M | $2.7M | -$120.2K | -$50.1K | -$36.9K | |
| Cash From Financing | $12M | $7.4M | $7.3M | $5.2M | $2.5M | |
| Free Cash Flow | -$7.8M | -$13.3M | -$11.1M | -$3M | -$2.7M | |
NMTC
Sector
Market Cap
$23.7M
$46.1M
Price % of 52-Week High
44.76%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-18.98%
-0.6%
1-Year Price Total Return
-43.4%
-30.52%
Beta (5-Year)
0.688
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.76
200-day SMA
Sell
Level
$0.92
Bollinger Bands (100)
Sell
Level
0.72 - 0.94
Chaikin Money Flow
Sell
Level
-14.7M
20-day SMA
Buy
Level
$0.71
Relative Strength Index (RSI14)
Buy
Level
52.17
ADX Line
Sell
Level
25.23
Williams %R
Neutral
Level
-47.7804
50-day SMA
Sell
Level
$0.81
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
27.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-21.7754)
Sell
CA Score
(Annual)
Level (-8.2423)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (13.4507)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Stock Forecast FAQ
In the current month, NMTC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NMTC average analyst price target in the past 3 months is --.
-
Where Will NeuroOne Medical Technologies Stock Be In 1 Year?
According to analysts, the consensus estimate is that NeuroOne Medical Technologies share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About NeuroOne Medical Technologies?
Analysts are divided on their view about NeuroOne Medical Technologies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NeuroOne Medical Technologies is a Sell and believe this share price will drop from its current level to --.
-
What Is NeuroOne Medical Technologies's Price Target?
The price target for NeuroOne Medical Technologies over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NMTC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NeuroOne Medical Technologies is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NMTC?
You can purchase shares of NeuroOne Medical Technologies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NeuroOne Medical Technologies shares.
-
What Is The NeuroOne Medical Technologies Share Price Today?
NeuroOne Medical Technologies was last trading at $0.83 per share. This represents the most recent stock quote for NeuroOne Medical Technologies. Yesterday, NeuroOne Medical Technologies closed at $0.77 per share.
-
How To Buy NeuroOne Medical Technologies Stock Online?
In order to purchase NeuroOne Medical Technologies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is down 3.24% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 4.09% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.26% over the past day.
